| Description | Halopemide is a potent inhibitor of PLD (IC50 = 220 and 310 nM for human PLD1 and PLD2). Halopemid is an antagonist of dopamine receptors. Halopemid can be used in psychotropic research. |
| In vitro | In transdifferentiated MOVAS cells, Halopemide (1-2 μM; 21 days) influences calcification[1]. |
| In vivo | 在大多数接受测试的猴子中，Halopemide（10 mg/kg; p.o.）会引起运动障碍[2]。 |
| Target activity | PLD1:220 nM, PLD2:310 nM |
| molecular weight | 416.88 |
| Molecular formula | C21H22ClFN4O2 |
| CAS | 59831-65-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (131.93 mM) |
| References | 1. Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234(4):4825-4839. 2. Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7. 3. Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17. |